TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

New Data Underscore Importance of Looking for HCM Before Scheduling TAVR

Reported in 2018 by anesthesiologists at the University of Florida College of Medicine in Gainesville, the case suggested a message to TAVR operators: “Vigilance and a high degree of suspicion” are critical for avoiding the potentially severe hemodynamic consequences of HCM associated with aortic stenosis, the authors asserted (J Med Case Rep 2018;18;12[1]:372).

Study reveals similar 5-year outcomes for TAVR, SAVR

An analysis of PARTNER 2 data published in the New England Journal of Medicine Jan. 29 suggests five-year post-op outcomes are similar among heart patients who undergo either transcatheter or surgical aortic valve replacement.

Thumbnail

Cardiology’s Challenge for the 2020s: Turning the Trend on Rising Mortality

The latest numbers on cardiovascular deaths put the focus on innovative ways to point the trend line down again.

Thumbnail

TAVR linked to better long-term health status than SAVR

Patients with severe aortic stenosis who undergo TAVR enjoy a minor but significant sustained health benefit that isn’t mirrored in patients who opt for surgical AVR, according to research reported at TCT 2019 in San Francisco.

Thumbnail

Transcarotid Access: The Future of Non-femoral TAVR?

The transcarotid approach to TAVR is becoming more common, according to research presented at TVT.19.

Thumbnail

Paravalvular regurgitation rates slashed with SAPIEN 3 heart valves

The mortality risk associated with moderate to severe PVR was consistent with previous studies, wrote lead author Philippe Pibarot, DVM, PhD, and colleagues, but the rate of moderate or worse PVR dropped threefold when compared to previous SAPIEN valves.
Thumbnail

TCT 2017: Frailty provides prognostic value for TAVR patients—but better risk scores are needed

DENVER — Measuring frailty could lead to more accurate predictions of outcomes following transcatheter aortic valve replacement (TAVR) than a validated risk algorithm, according to research presented Oct. 30 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Thumbnail

5 topics to watch at TCT 2017

The 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium kicks off in Denver in less than two weeks. In preparation, Gregg W. Stone, MD, co-director of medical research and education at the Cardiovascular Research Foundation, provided some expected highlights of this year’s session Oct. 16 during a press briefing.

Displaying 401 - 408 of 417

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.